All AbMole products are for research use only, cannot be used for human consumption.
INF39 is a nontoxic, irreversible NLRP3 inhibitor able to decrease interleukin-1β release from macrophages. INF39 (INF39) significantly inhibits ATP- and nigericin-induced IL-1β release. INF39 potentially reacts with Cys-SH residues in the active site of cysteine protease caspase-1, but does not directly target caspase-1 activity. The inhibition of NLRP3 inflammasome complex with INF39 dose-dependently attenuates the decrease in colonic length (-19, -13 and -8% at 12.5, 25, 50 mg/kg, respectively). Rats treated with INF39 displays a significant reduction of macroscopic damage score (4.7 at 12.5 mg/kg, 3.1 at 25 mg/kg, and 2.8 at 50 mg/kg). Oral administration of INF39 reduces colonic myeloperoxidase, IL-1β, and TNF Levels in DNBS-treated rats.
*The compound is unstable in solutions, freshly prepared is recommended
| Molecular Weight | 224.68 |
| Formula | C12H13ClO2 |
| CAS Number | 866028-26-4 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related NLR Products |
|---|
| SLC3037
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. |
| FK 565
FK 565 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist. |
| NBC19
NBC19 is an NLRP3 inflammasome inhibitor with an IC50 of 60 nM in differentiated THP1 cells. |
| NT-0249
NT-0249 is an orally active NLRP3 inhibitor. |
| BAL-0028
BAL-0028 is a NLRP3 activation inhibitor with a IC50 value of 25 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
